Navigation Links
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
Date:10/31/2011

a result of various important factors, including risks relating to: our plans to develop and commercialize EXPAREL; the success and timing of our commercial launch of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and our ability to serve those markets; our commercialization and marketing capabilities; and other factors discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2010, and in other filings that we periodically make with the SEC. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Contacts:Company Contact:
Pacira Pharmaceuticals, Inc.
James S. Scibetta, 973-254-3560

or

Investor Contact:
Pure Communications Inc.
Jennifer Beugelmans, 646-596-7473Pacira Pharmaceuticals, Inc.Consolidated Statement of Operations(unaudited)(in thousands, except share and per share amounts)Three Months

Ended September 30, Nine Months
Ended September 30, 2011201020112010 Revenues: Supply revenue

$
,682$
2,744$
4,868$
7,127 Royalties

9221,0232,7432,693 Collaborative licensing and development revenue

1,3527653,8452,551 Total revenues

3,9564,53211,45612,371 Operating expenses: Cost of revenues

3,3573,57310,13810,168 Research and development

4,3445,71612,23714,954 Selling, general and administrative

4,9881,69413,4653,948 Total operating expenses


'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014 Nonin Medical, Inc., ... in noninvasive medical monitoring, today announced that the Food ... 3231 OEM/eHealth finger pulse oximeter for use in ... oximeter plugs into a telemedicine hub or kiosk through ... rate in pediatric to adult patients. The Model 3231 ...
(Date:8/28/2014)... R.I. , Aug. 28, 2014  In recognition ... developing health complications from the flu, pneumonia, shingles ... ® have declared September to be Senior ... they age, it is important that adults ages ... on their vaccinations. CVS pharmacists and MinuteClinic nurse ...
(Date:8/28/2014)... Pa. , Aug. 28, 2014  Robotic ... patients, and media, both for the promise of ... safety. The quick deployment of surgical robots and ... are prompting facilities to evaluate their robotic surgery ... entire surgical team.    ECRI Institute ...
Breaking Medicine Technology:Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 2September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 3September is Senior Vaccination Month at CVS/pharmacy and MinuteClinic 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... 25, 2007 - Reata,Pharmaceuticals, Inc. today announced ... company's Synthetic Triterpenoid programs in,the May 2007 ... The article, "Triterpenoids and rexinoids as multifunctional,agents ... by researchers,and Reata scientific collaborators from the ...
... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
Cached Medicine Technology:Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
(Date:8/28/2014)... To kick off the fall season of sporting ... retailers across the country are offering 0% financing for ... Tub Tailgate Event is from August 29th-September 15th. ... and to apply early! , As the leader in ... of outdoor hot tubs with exclusive features at your ...
(Date:8/28/2014)... repairing nerves with adhesives, most researchers place glue directly ... fix the nerve ends well and allows glue to ... cylindrical. However, it is difficult to insert the nerve ... and there is frictional resistance. Xiangdang Liang and co-workers ... special conduit for the adhesive technique and defined the ...
(Date:8/28/2014)... 2014 One in every 200 Ontarians has been ... of people living with the disease increasing by 64 ... study by researchers at the Institute for Clinical Evaluative ... and the Ottawa Hospital Research Institute. That puts Ontario ... world. , The study, published this week in ...
(Date:8/28/2014)... 28, 2014 BCC Research ( http://www.bccresearch.com ... SYSTEMS: TECHNOLOGIES AND GLOBAL MARKETS , the global market ... in 2013. Driven by the need for replacement of ... in emerging geographies, the market is expected to grow ... (CAGR) of 8.5% from 2013 through 2018. , While ...
(Date:8/28/2014)... Parker Waichman LLP, a national personal ... to ensure that the heroes of 9/11 are never ... WTC victims who developed 9/11-related cancer was reaffirmed by ... (GAO). According to a statement issued by 9/11 ... entitled “World Trade Center Health Program: Approach Used to ...
Breaking Medicine News(10 mins):Health News:Ontario has one of the highest rates of IBD in the world 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 2Health News:Global Market for Surgical Navigation Systems Expected to Reach $631.9 Million in 2018; ENT Systems Segment Leading With 10.4% CAGR 3Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 2Health News:GAO Report Reaffirms Decision to Add Cancers to List of Illnesses Covered under the Zadroga Act, Parker Waichman LLP Comments 3
... ORLEANS, Sept. 28 Sanarus Medical today announced ... centers across,the country. These Centers, including breast care ... with Sanarus to,increase the awareness and availability of ... breast tumors, known as,fibroadenomas. Sanarus will host a ...
... Sept. 28 Today, at the Clinton,Global Initiative, ... total value is $1,000,000. Fulvio,Renoldi Bracco, Bracco AMT,s ... company and said that the partnership would provide ... Heart Hospital, in,Changchun City, Jilin Province, China -- ...
... N.J., Sept. 28 Whether she is giving a,keynote ... Esther Paik Goodhart conveys optimism and possibility. "Only ... I have,",says Goodhart with a warm laugh, "I,m a ... I teach Hebrew at three temples,and I,m running for ...
... Inc. ("NAI") (Nasdaq: NAII ), a leading,formulator, manufacturer ... be unable to file its Annual Report on,Form 10-K ... a timely basis because,it requires additional time to complete ... Annual Report on Form 10-K no later than,October 15, ...
... 28 Amid increasing pressure to combat,childhood obesity, the ... eleven-year-olds will lumber forward, breaking the $1,billion mark in ... the,U.S., a new report from market research publisher Packaged ... of kids, licensed food and,beverage products rose 9%, from ...
... University of Kentucky Center for Poverty Research has received ... Association of America Foundation (MOWAAF) to study the economic ... in America. , James Ziliak, Gatton Endowed Chair of ... at UK, part of the Gatton College of Business ...
Cached Medicine News:Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2Health News:Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI 2Health News:Humor and Hope Sustain NJ Woman Through Disabling Movement Disorder, Election Campaign 2Health News:Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008 2Health News:Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008 3Health News:Pressure to Promote Healthier Eating to Cause Minor Growing Pains for Kids' Licensed Foods and Beverages 2Health News:Center for Poverty Research to study senior hunger in America 2
... Unique product designed for LASIK surgery ... to irrigate the corneal interface and/or stromal ... the flap and helps elevate the flap ... 7/8in (.40 x 22mm) Formed 9mm from ...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... x 22mm) Formed 9mm from end. Two ...
... designed for LASIK surgery and other ... irrigate the corneal interface and/or stromal ... under the flap and helps elevate ... multi-directional irrigation. 25G x 7/8in (.50 ...
... Cannula tip is specially ... insertion through wound and manipulation ... x 3.5mm, flexible tubing 25cm, ... 2mm. Unique annular rings ...
Medicine Products: